Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia & Upjohn acquires Glyset oral antidiabetic Rx, OTC rights from Bayer.

This article was originally published in The Tan Sheet

Executive Summary

GLYSET ORAL ANTIDIABETIC OTC RIGHTS TO P&U under an agreement with Bayer to acquire marketing rights to Rx miglitol in the U.S., Canada, Australia and New Zealand, Pharmacia & Upjohn announced Aug. 31. In addition to rights to sell Glyset as a prescription treatment for Type II diabetes, the deal "provides P&U with rights to market Glyset for over-the-counter use in the future," the company said. This stipulation applies to all markets covered by the agreement.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel